

**MED LIFE S.A.**

Registered Office: Bucharest, 365, Calea Grivitei, 1st district, Romania  
Unique Registration Code at the National Office of Trade Registry: 8422035  
Order number on the Trade Registry: J1996003709402  
Subscribed and paid-in share capital: 132,870,492 RON



No. 34 / 29 May 2026

**To: BUCHAREST STOCK EXCHANGE  
FINANCIAL SUPERVISORY AUTHORITY**

**ANNOUNCEMENT**Report Date: **29 May 2026**Name of the issuing company: **MED LIFE S.A. ("MedLife" or "the Company")**Registered Office: **Bucharest, 365 Calea Grivitei, district 1, Romania**Telephone / Fax number: **0374 180 470**Unique Registration Code at the National Office of Trade Registry: **8422035**Order number on the Trade Registry: **J1996003709402**EUID: **ROONRC.J1996003709402**Subscribed and paid-in share capital: **RON 132,870,492**Total number of shares: **531,481,968 (out of which 665,983 shares without voting rights and 530,815,985 shares with voting rights)**Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category****MedLife reports a 10% increase in pro-forma consolidated turnover in the first 3 months of the year. The evolution was mainly supported by organic growth**

- *MedLife recorded in Q1 2026 a consolidated pro-forma turnover of RON 856 million, up 10% compared to the same period of the previous year.*
- *The Group reports growth in most business lines, with the strongest performances being recorded by the clinics division, followed by the corporate and hospitals divisions.*
- *The company maintains a prudent approach for the upcoming period, while also having the investment capacity and financial flexibility to pursue potential acquisition or expansion opportunities.*
- *The Group is focused on growth in the areas of technology, genomics, and digitalization, accelerating the transformation of medical services through innovative solutions and projects with long-term impact.*
- *In the immediate future, MedLife will launch several innovative products designed to help patients monitor their health more effectively and improve their lifestyle, based on an integrated set of information ranging from genetic, biometric, and medical data to psychometric data, nutrition, and sleep patterns.*

**Bucharest, May 29<sup>th</sup>, 2026:** MedLife, the leader of the private medical services market in Romania and the only company with Romanian capital among the top of private medical services operators listed on the stock exchange, presents the financial results for the first quarter of 2026 and announces a positive dynamic despite the economic, social and political context characterized by volatility and investment prudence at regional level.

In the first three months of the year, MedLife Group recorded a pro-forma consolidated turnover of RON 856 million, up 10% compared to the same period last year, an evolution that confirms the resilience of the medical sector and MedLife's ability to adapt quickly to market changes.

The Group achieved growth on most of its business lines. The most important advances in key divisions were recorded by clinics (+14%), corporate (+11.6%) and hospitals (+11.1%). According to MedLife representatives, the corporate division not only had a good start in 2026, but continues to strengthen its market share, amid the development of new solutions adapted to the current needs of employees and the expansion of the customer portfolio. In fact, MedLife has reached the threshold of 1 million medical subscriptions in its portfolio, respectively almost half of the total market. The laboratory division also recorded an increase of more than 10% in Q1 2026 compared to the same period last year.

*"The first months of the year confirmed that health remains a priority for Romanians, regardless of the economic, political or social context. At a time when many industries are experiencing slowdowns or even declines, MedLife continues to grow and perform at a sustained pace. The results reflect both the maturity of our business and the strategic investments made in recent years in infrastructure, technology and exceptional medical teams. In this context, we strongly believe that the demand for MedLife services will remain robust"* said **Mihai Marcu, President and CEO of MedLife Group.**

## MED LIFE S.A.

Registered Office: Bucharest, Calea Grivitei, no. 365, district 1, Romania  
Unique Registration Code at the National Office of Trade Registry: 8422035  
Order number on the Trade Registry: J40/3709/1996  
Subscribed and paid-in share capital: 5,536,270.5 RON



As for the outlook for the rest of the year, the CEO of MedLife is confident: *"We are looking at the next period with caution, but also with confidence. We have built a strong yet flexible group to navigate difficult economic contexts and remain relevant in the long term. At the same time, we have secured the necessary resources for possible investments and we remain attentive to the opportunities that may arise in the market. We will continue to strategically analyze each development direction and act according to the context."*

### **Innovation and genetics – strategic development directions of the Group**

In addition to consolidating its financial results, MedLife continued in the first quarter of the year to accelerate its innovation projects, reaffirming its position as an innovation-oriented company based on technology and personalized medicine. Among the most important initiatives carried out in Q1 2026 is the conduct of the first genomics study in Romania, a unique research initiative in the region, through which the company contributes to democratizing access to genetic testing and personalized prevention. At the same time, the Group has maintained investments in digitalization and the development of the technological ecosystem, with a focus on MedLife application and expansion of capabilities in the area of genomics and personalized medicine – directions considered strategic for the company's development in the medium and long term.

In parallel, MedLife Group continued the organic development process by opening the first Center Dedicated to Patients with Inflammatory Bowel Diseases, in Targul Mures, and at the same time, completed the acquisition of MEDSTAR through the Sfânta Maria network, a transaction that strengthens the Group's presence in the Transylvania region. The company also marked a new investment of over EUR 2 million in one of the most advanced robotic neurosurgery systems in Romania, now available at MedLife Sibiu.

*"Although the beginning of the year was marked by uncertainty and geopolitical risks, MedLife maintained its development path, continued to innovate and deliver value for patients, partners and shareholders. The current context forces us to remain balanced and adaptable. That is why we are preparing to operate simultaneously several scenarios and business approaches, adapted according to the evolution of the market in the next period and aligned with our strategic priorities", added Mihail Marcu.*

In the coming months, the company remains focused on the operational consolidation of the business and capitalizing on development opportunities, reaffirming its commitment to patients, employees and investors to remain an innovative leader in healthcare, through investments in sustainable development and continuous adaptation to evolving market needs.

### **Analysis of the Consolidated Comprehensive Income**

Sales for the 3-month period ended March 31, 2026, amounted to RON 853,140,353 higher by 9.7% compared to sales recorded in the first 3 months of 2025. The increase was mainly the result of growth in almost all of the Group's business lines, as well as the impact of the acquisitions completed by the Group in 2025.

Operating expenses include fixed and variable costs, as well as the cost of goods and materials used by the Group to provide services. The Group recorded operating expenses of RON 813,370,224 for the 3-month period ended March 31, 2026, representing an increase of 10.6%, or RON 78,131,602 as compared to the similar period of 2025. The Group's operating expenses as a percentage of total operating income represented 95.03% for 3 months 2026 and 94.36% for 3 months 2025.

Operating profit decreased by 3.3% in the 3-month period of 2026 compared to the same period of 2025, from RON 43,975,697 in 2025 to RON 42,520,629 in 2026.

Financial losses increased by RON 165,057 in 3-month period of 2026, from a loss of RON 26,410,748 as of March 31, 2025 to a loss of RON 26,575,805 as of March 31, 2026.

The net result for the 3-month period ended March 31, 2026 decreased with RON 1,794,276 compared to the corresponding period of 2025, from RON 10,560,011 for the 3-month period of 2025 to RON 8,765,735 for 3-month period of 2026.

## Analysis of the Consolidated Balance Sheet

Non-current assets amount to RON 2,593,221,654 as of March 31, 2026, registering an increase of RON 35,183,107, or 1.4%, compared to December 31, 2025. The increase was mainly due to increase in goodwill with 30,849,676 RON following the acquisition of Medstar SRL.

Current assets increased by RON 39,686,855, or 5.6%, from RON 702,888,150 as of December 31, 2025 to RON 742,575,005 as of March 31, 2026.

Current liabilities (excluding interest-bearing items) increased by RON 29,244,890, or 4.4%, from RON 662,703,593 as of December 31, 2025 to RON 691,948,483 as of March 31, 2026.

Interest-bearing debt increased by RON 39,765,876, or 2.1%, from RON 1,931,339,624 as of December 31, 2025 to RON 1,971,105,500 as of March 31, 2026.

## Operational Key Performance Indicators

Business line	Info	Q1	
		2025	2026
Clinics	<b>Revenue</b>	<b>290,650,198</b>	<b>331,224,234</b>
	Visits	1,190,616	1,314,401
	Avg fee	244.1	252.0
Hospitals	<b>Revenue</b>	<b>209,035,384</b>	<b>232,283,181</b>
	Patients	51,538	54,496
	Avg fee	4,055.9	4,262.4
Laboratories	<b>Revenue</b>	<b>86,712,946</b>	<b>96,027,967</b>
	Analyses	2,614,813	2,926,981
	Avg fee	33.2	32.8
Corporate	<b>Revenue</b>	<b>75,135,981</b>	<b>83,844,911</b>
	Subscriptions	886,378	949,894
	Avg fee	84.8	88.3
Dentistry	<b>Revenue</b>	<b>30,065,714</b>	<b>29,254,822</b>
	Visits	45,011	43,437
	Avg fee	668.0	673.5
Pharmacies	<b>Revenue</b>	<b>18,259,974</b>	<b>23,834,956</b>
	Clients	115,512	114,366
	Sales per client	158.1	208.4
Others	<b>Revenue</b>	<b>67,773,125</b>	<b>56,670,281</b>
<b>Total</b>		<b>777,633,322</b>	<b>853,140,353</b>

## Report availability

The Q1 2026 results report is available on the company's website, in the Investor Relations section / Reports and Presentations / Financial Reports (<https://www.medlife.ro/investor-relations/reports-and-presentations/financial-reports>) and on the Bucharest Stock Exchange's website (symbol **M**).

## Results presentation conference call

We remind you that MedLife will hold a conference call for analysts and investors to present the financial results, on 29 May 2026, starting 4:00 p.m. (Romanian time). The conference call will be held in English, and the transcript will be available afterwards, on MedLife's website, in the Investor Relations section / Reports and Presentations / Financial Reports. In order to participate to the event, please contact us at [investors@medlife.ro](mailto:investors@medlife.ro).